Disease-A-Month
Volume 49, Issue 1 , Pages 39-48 , January 2003

Recombinant factor VIIa (NovoSeven®) as a hemostatic agent

References 

  1. Aberg M, Hedner U, Bergentz SE. Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg. 1979;189:243–247
  2. Bajzar L, Nesheim M. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem. 1993;268:8608–8616
  3. Bech R, Nicolaisen EF, Anderson PM, et al.  Recombinant factor VIIa for the treatment of congenital factor VII deficient patients. Thromb Haemost. 1989;62:55; (abstr)
  4. Béguin S, Kumar R. Thrombin, fibrin and platelets: A resonance loop in which von Willebrand factor is a necessary link. Thromb Haemost. 1997;78:590–594
  5. Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost. 1989;61:25–29
  6. Bernstein DE, Jeffers L, Erhardtsen E, et al.  RFVIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology. 1997;113:1930–1937
  7. Berntorp E, Stigendal L, Lethagen S, et al.  NovoSeven in warfarin-treated patients. Blood Coagul Fibrinolysis. 2000;11(suppl):S113–S115
  8. Biggs R, MacFarlane RG. Human Blood Coagulation and its Disorders. ed 3. Oxford, UK: Blackwell; 1962;
  9. Blombd ̈ack B, Carlsson K, Fatah K, et al.  Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation. Thromb Res. 1994;75:521–538
  10. Broze GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88:3815–3823
  11. Cawthern KM, van't Veer C, Lock JB, et al.  Blood coagulation in hemophilia A and hemophilia C. Blood. 1998;91:4581–4592
  12. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost. 1999;82:1778
  13. Ciavarella N, Schiavoni M, Valenzano E, et al.  Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand‘s disease and an inhibitor against von Willebrand factor. Haemostasis. 1996;26(suppl 1):150–154
  14. Deveras RAE, Kessler CM. Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized ratios (INR) and prothrombin times induced by warfarin. Blood. 2000;96(suppl 1, abstr 2745):638a
  15. Erhardtsen E, Nony P, Dechavanne M, et al.  The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis. 1998;9:741–748
  16. Essex D, Bluth M, Gloster E, et al.  Successful use of recombinant factor VIIa (rFVIIa) for trauma-associated massive hemorrhage. Blood. 2000;96(suppl 1, abstr):1150
  17. Fressinaud E, Sigaud-Fiks M, Le Boterff C, et al.  Use of recombinant factor VIIa (NovoSeven) for dental extraction in a patient affected by platelet-type (pseudo) von Willebrand disease. Haemophilia. 1998;4:3; (abstr 573)
  18. Gralnick HR. Massive transfusion. In:  Colman RW,  Hirsch J,  Marder VJ, et al. editor. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott; 1982;p. 612–622
  19. He S, Blombäck M, Hedner U. Effect of rFVIIa on the permeability of fibrin gel. Blood. 2000;96(suppl 1, abstr 1120):261a
  20. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost. 1999;82:531–539
  21. Hedner U, Bergqvist D, Ljungberg J, et al.  Haemostatic effect of factor VIIa in thrombocytopenic rabbits. Blood. 1985;66:132
  22. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci. 1998;19:163–176
  23. Hendriks HGD, Meijer K, de Wolf JTH, et al.  Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation. 2001;71:402–405
  24. Ingerslev J, Knudsen L, Hvid I, et al.  Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia. 1997;3:215–218
  25. Jeffers L, Balart L, Erhardtsen E, et al.  Efficacy and safety of rFVIIa in patients with severe coagulopathy undergoing laparoscopic liver biopsy. Blood. 1999;10(suppl 1, abstr 1043):A236
  26. Kenet G, Walden R, Eldad A, et al.  Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879
  27. Kjalke M, Ezban M, Monroe DM, et al.  High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol. 2001;114:114–120
  28. Kjalke M, Monroe DM, Hoffman M, et al.  High-dose factor VIIa restores platelet activation and total thrombin generation in a model system mimicking hemophilia A or B conditions. Thromb Haemost. 1999;951:303
  29. Kristensen J, Killander A, Hippe E, et al.  Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26:159–164
  30. Laffan MA, Cummins M. Recombinant factor VIIa for intractable surgical bleeding. Blood. 2000;96(suppl 1, abstr 4048):85b
  31. Lusher J, Ingerslev J, Roberts H, et al.  Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998;9:119–128
  32. Mariani G, Mannucci PM, Mazzucconi MG, et al.  Treatment of congenital factor VII deficiency with a new concentrate. Thromb Haemost. 1978;39:675–682
  33. Mariani G, Testa MG, Di Paolantonio T, et al.  Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang. 1999;77:131–136
  34. McDonagh J, Fukue H. Determinants of substrate specificity for factor XIII. Semin Thromb Hemost. 1996;22:369–376
  35. Monroe DM, Hoffman M, Oliver JA, et al.  Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–547
  36. Nesheim M, Wang W, Boffa M, et al.  Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 1997;78:386–391
  37. Oliver JA, Monroe DM, Roberts HR, et al.  Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol. 1999;19:170–177
  38. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost. 1998;80:352
  39. Poon M, Demers C, Jobin F, et al.  Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999;94:3951–3953
  40. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a “prima ballerina.”. Thromb Haemost. 1995;74:7–17
  41. Reverter JC, Béguin S, Kesels H, et al.  Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis.”. J Clin Invest. 1996;98:863–874
  42. Stump DC, Strauss RG, Henriksen RA, et al.  Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion. 1985;25:349–354
  43. Vlot AJ, Ton E, Mackaay AJ, et al.  Treatment of severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med. 2000;108:421–423
  44. Weisel JW, Veklich Y, Collet JP, et al.  Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost. 1999;82:277–282
  45. White B, McHale J, Ravi N, et al.  Successful use of recombinant FVIIa (NovoSeven) in the management of intractable post-surgical intra-abdominal hemorrhage. Br J Hematol. 1999;107:677–678

PII: S0011-5029(03)90013-7

doi: 10.1016/S0011-5029(03)90013-7

Disease-A-Month
Volume 49, Issue 1 , Pages 39-48 , January 2003

Article Tools